Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Earnings out 4/3/08 ?

SGE1,

I appreciate the respect you’ve shown in your post and I will always show the same respect to you and everyone else here. Though,I would like to make a few statements.

1st I don’t have any motive here other than to discuss the subjects of PTSC interesting to me. (I don’t produce FUD or Bash, so respectfully please drop that notion in a line of discussion to me.)

2nd When you are done with a subject does that mean that we can’t discuss it on this board anymore?

3rd I’m quietly tired of a few of the discussions on this board myself, but I don’t intend to criticize those that discuss something they deem important to them. I just skim though it and move on. I realize they probably have money in this and that fact makes people irrational, at times.

4th Finally, I hope you don’t take any of my statements here as mean spirited, I just feel that we should have the freedom to openly discuss a topic as much as we care to, after all that is the point of the board, I hope.

Hope this didn’t come off sounding the wrong way, but it is the way I feel.

Reading through your post it does seem that we agree on the core issues concerning share buybacks, mergers and/or acquisitions. On April 9th Rick will be rapidly approaching the half way point, having spent 42 of the 120 days of allotted time (the 30 days I mentioned earlier were business days) to put a deal in place. I’m sure there was some discussion with Rick before the board set the 120-day limit and he agreed that the time limit was acceptable. CEO’s of Rick caliber will avoid embarrassment like a plague. This 120 day time line in my opinion was the boards’ way of saying let’s get on with a long-term business plan for PTSC.

 

BTW- I do enjoy reading most of your comments here. GLTY

Accentuate the positive!

Bluewing

Share
New Message
Please login to post a reply